ArticleWorld journal of urology2026
Association between SGLT2 inhibitor use and Fournier's gangrene after genital or perineal surgery: a retrospective cohort study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFournier's gangrene (FG) is a rare but life-threatening infectious complication of surgery in the perineum and genital region. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been linked to genital infections in case reports, but the postoperative risk of FG in patients receiving these medications is unclear. We evaluated whether preoperative exposure to SGLT2is increases FG risk following genital or perineal surgery.
methodsWe conducted a retrospective cohort study using the TriNetX Research Network, including adults who underwent genital or perineal surgery between 2013 and 2025. Exposure was defined as any SGLT2i prescription recorded at least 5 days before surgery. Patients with prior FG or debridement for necrotizing infection were excluded. The primary outcome was FG within 1 month postoperatively; secondary outcomes included risk over 3 months and 1 year. Cohorts were balanced using propensity score matching for demographic factors and comorbidities.
resultsOf 510,330 eligible patients, 7575 received SLGT2is and 502,755 did not. After matching, each cohort included 7572 patients. At 1 month, FG occurred in 13 (0.17%) exposed patients and 20 (0.27%) non-exposed patients (RR 0.65, 95% CI 0.32-1.30, p = 0.2). Results were similar at 3 months and 1 year. A subgroup analysis among patients with diabetes yielded results consistent with the primary analysis.
conclusionsPreoperative use of SGLT2is was not associated with increased postoperative FG risk following perineal or genital surgery. If validated, these findings may reassure clinicians and patients that SGLT2i use is safe in surgical patients, though protective medication management practices may contribute to these outcomes.
Indexed as
Identifiers
42258009What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.